[Adjuvant chemotherapy and/or hormone therapy after radical prostatectomy for high-risk prostate cancer].
Cancer prostate is heterogeneous and may require a risk-adjusted approach to therapy. Improved survival rates are reported for adjuvant chemotherapy alone or in combination with hormone therapy. A specific gene expression signature can be used to identify and predict response to adjuvant standard hormone therapy or hormone therapy and chemotherapy after radical prostatectomy.
Paule
Bernard
B
Service d'Urologie, Hôpital Henri Mondor, Créteil, France. bepaule@wanadoo.fr
de la Taille
Alexandre
A
D017024:Chemotherapy, Adjuvant; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011446:Prospective Studies; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D006728:Hormones